Literature DB >> 2381537

Excessive muscular fatigue in patients with spastic paraparesis.

R G Miller1, A T Green, R S Moussavi, P J Carson, M W Weiner.   

Abstract

We used intermittent tetanic contractions and 31P magnetic resonance spectroscopy to investigate human tibialis anterior muscle metabolism and fatigability in a group of patients with spastic paraparesis and in normal controls. During intermittent tetanic stimulation, the decline in tension was significantly greater in patients than in controls, and the half-relaxation time of the tetanus was more prolonged. Moreover, the decline in phosphocreatine and intracellular pH was significantly greater in patients than in controls. These observations suggest that biochemical changes in the muscles of patients with upper motor neuron lesions may contribute to their excessive fatigability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2381537     DOI: 10.1212/wnl.40.8.1271

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Recommendations for physical activity in patients with multiple sclerosis.

Authors:  J H Petajan; A T White
Journal:  Sports Med       Date:  1999-03       Impact factor: 11.136

2.  Funktionelle Elektrostimulation Paraplegischer Patienten.

Authors:  Helmut Kern
Journal:  Eur J Transl Myol       Date:  2014-07-08

Review 3.  Factors affecting the rate of phosphocreatine resynthesis following intense exercise.

Authors:  Shaun McMahon; David Jenkins
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

4.  Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis.

Authors:  K R Sharma; J Kent-Braun; M A Mynhier; M W Weiner; R G Miller
Journal:  Muscle Nerve       Date:  1995-12       Impact factor: 3.217

5.  Deep gray matter and fatigue in MS: a T1 relaxation time study.

Authors:  G Niepel; Ch R Tench; P S Morgan; N Evangelou; D P Auer; C S Constantinescu
Journal:  J Neurol       Date:  2006-03-13       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.